Journal of Clinical Densitometry
Volume 12, Issue 3 , Pages 287-291 , July 2009

Implementation of Osteoporosis Screening Guidelines in Prostate Cancer Patients on Androgen Ablation

  • Lindsay S. Van Tongeren

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Lindsay S. Van Tongeren, MD, Department of Internal Medicine, University of British Columbia, Gordon & Leslie Diamond Health Care Center, 10th floor, 2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.
    • Department of Internal Medicine, University of British Columbia, Vancouver, Canada
    • ,
  • Graeme G. Duncan

      Affiliations

    • Division of Endocrinology, University of British Columbia, Vancouver, Canada
    • ,
  • David L. Kendler

      Affiliations

    • Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, Canada
    • ,
  • Howard Pai

      Affiliations

    • Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, Canada

Received 7 December 2008 ,Revised 20 April 2009 ,Accepted 2 May 2009.

References 

  1. Lu-Yao GL, Albertson PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300:173–181
  2. Shahinian VB, Kuo Y, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615–1624
  3. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:15
  4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet. 2002;360:103–106
  5. Vanderschueren D, Gaytant J, Boonen S, Venken K. Androgens and bone. Curr Opin Endocrinol Diabetes Obes. 2008;15:250–254
  6. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106:1553–1560
  7. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999;54:607–611
  8. Malcolm JB, Derweesh IH, Kincade MC, et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol. 2007;14:3551–3559
  9. Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69:500–504
  10. Shahinian VB, Kuo Y, Jean L, et al. Risk of fracture after androgen deprivation for prostate cancer. NEJM. 2005;352:154–164
  11. Melton LJ, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol. 2003;169:1747–1750
  12. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci. 1992;304:4–8
  13. Basaria S, Lieb J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol. 2002;56:779–786
  14. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001;57:127–132
  15. Morote J, Martinez E, Trilla E, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol. 2003;44:661–665
  16. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724–1728
  17. Townsend MF, Sanders WH, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997;79:545–550
  18. López AM, Pena MA, Hernández R, et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005;16:707–711
  19. Abrahamsen B, Nielsen MF, Eskildsen P, et al. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int. 2007;100:749–754
  20. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–7903
  21. Duncan GG, Corbett T, Lukka H, et al. GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol. 2006;13:2962–2966
  22. Francke AL, Smit MC, de Veer AJE, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008;8:38
  23. Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527–530
  24. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003;362:1225–1230
  25. Brown JP, Josse RG The Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 Suppl):S1–S34
  26. Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2008;148:680–684
  27. Jaglal SB, McIsaac WJ, Hawker G, et al. Patterns of use of the bone mineral density test in Ontario, 1992–1998. CMAJ. 2000;163:1139–1143
  28. Vanasse A, Dagenais P, Niyonsenga T, et al. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord. 2005;6:1471–2474
  29. Rideout R, Hawker GA. Use of bone densitometry by Ontario family physicians. Osteoporos Int. 2000;11:393–399

PII: S1094-6950(09)00147-4

doi: 10.1016/j.jocd.2009.05.001

Journal of Clinical Densitometry
Volume 12, Issue 3 , Pages 287-291 , July 2009

Article Tools

* Image Usage & Resolution